Navigating Your Tests: Blood, Urine, and Imaging
At a Glance
ADKH-RRAGD evaluation combines RRAGD genetic testing with blood and urine tests for mineral wasting, FEMg, echocardiography and cardiac MRI for heart changes, and kidney ultrasound to check for nephrocalcinosis over time.
Because this syndrome affects both the heart and the kidneys, your diagnostic journey involves multiple layers of testing. Doctors use these tests to look for a “kidney leak” of essential minerals and to assess the physical structure and pumping strength of your heart [1][2].
The Blueprint: Genetic Testing
Genetic testing is used to confirm a diagnosis of ADKH-RRAGD. A targeted kidney/cardiomyopathy panel or exome sequencing is typically used to find a pathogenic or likely pathogenic mutation in the RRAGD gene [1][3]. A variant of uncertain significance (VUS) does not confirm the syndrome on its own.
Identifying your specific variant is important because it helps your doctors understand which “chapter” of the disease (heart or kidney) might need more frequent monitoring [2].
The Kidney Balance: Blood and Urine Tests
To understand how your kidneys are functioning, your care team will look at several key markers in your blood and urine.
- Serum Magnesium and Potassium: These are standard blood tests. In this syndrome, your blood levels of these minerals are often chronically low because the kidneys are not reabsorbing them correctly [1][4].
- Hypercalciuria: This means there is too much calcium in your urine. This is a helpful “clue” that distinguishes this syndrome from others, like Gitelman syndrome, where urine calcium is usually low [4][5]. Note that this is a variable finding and may not occur in everyone.
Reviewing Your Labs: The FEMg “Leak” Test
A critical part of your diagnosis is the Fractional Excretion of Magnesium (FEMg). This is a calculation that compares how much magnesium is in your blood versus how much is being “dumped” into your urine [6].
You can review these results with your doctor by looking for this pattern:
- Low Blood Magnesium + High FEMg: Normally, if your blood magnesium is low, your kidneys should “hold on” to every bit of magnesium they can, making the FEMg very low (usually less than 2%).
- The Diagnostic Sign: If your blood magnesium is low but your FEMg is greater than 2%, it may support a diagnosis of renal magnesium wasting when interpreted by a specialist. Thresholds vary by laboratory and clinical context, and it must be evaluated alongside appropriate renal function [7].
Note: Your FEMg can be “falsely” high if you have just taken a magnesium supplement or if you are on a diuretic medication, so these tests should be interpreted carefully by your specialist [8][9].
The Heart Profile: Cardiac Imaging
Heart tests look for dilated cardiomyopathy (DCM), where the heart muscle becomes thin and its pumping chambers become enlarged [10].
- Echocardiogram (Echo): This is an ultrasound of the heart. Doctors look for dilation (enlargement of the chambers) and measure your Left Ventricular Ejection Fraction (LVEF) [10].
- LVEF is the percentage of blood the heart pumps out with each beat. While normal ranges vary by method and laboratory, a normal LVEF does not exclude early cardiomyopathy, and a reduced number indicates a weakened heart muscle [11].
- Cardiac MRI (CMR): This provides a more detailed look at the heart tissue. A key finding doctors look for is Late Gadolinium Enhancement (LGE). LGE can indicate fibrosis or other tissue abnormalities, but it is not itself proof of permanent scar or a validated RRAGD-specific prognostic marker [12][13][14]. Renal function must be considered before gadolinium contrast is used.
Imaging the Kidneys: Ultrasound
In addition to blood work, you will likely have a renal ultrasound. This imaging test checks for nephrocalcinosis, which is a buildup of calcium deposits within the kidney tissue [1][4]. While these are not usually kidney stones that pass through the urine, they are a sign that the kidneys have been handling minerals incorrectly for some time [4]. Regular ultrasounds help your team monitor if this buildup is stable or progressing.
Common questions in this guide
How is kidney tubulopathy-dilated cardiomyopathy syndrome confirmed?
What does a high FEMg mean when my blood magnesium is low?
Can supplements or medicines affect my FEMg result?
What can an echocardiogram show in ADKH-RRAGD?
What does late gadolinium enhancement on a cardiac MRI mean?
Why is a kidney ultrasound used to check for nephrocalcinosis?
One line in your results can change your plan.
Identifying the RRAGD variant helps show which organ, heart or kidney, might need more frequent monitoring. We check your results against the latest research to help you prepare for what’s next.
Get notified when new evidence is published on Kidney tubulopathy-dilated cardiomyopathy syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (14)
- 1
mTOR-Activating Mutations in RRAGD Are Causative for Kidney Tubulopathy and Cardiomyopathy.
Schlingmann KP, Jouret F, Shen K, et al.
Journal of the American Society of Nephrology : JASN 2021; (32(11)):2885-2899 doi:10.1681/ASN.2021030333.
PMID: 34607910 - 2
RRAGD-Associated Autosomal Dominant Kidney Hypomagnesemia with Cardiomyopathy: A Review on the Clinical Manifestations and Therapeutic Options.
Trepiccione F, Sambri I, Ruggiero B, et al.
Kidney & blood pressure research 2024; (49(1)):637-645 doi:10.1159/000539889.
PMID: 38901414 - 3
Exome Sequencing and Identification of Phenocopies in Patients With Clinically Presumed Hereditary Nephropathies.
Riedhammer KM, Braunisch MC, Günthner R, et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation 2020; (76(4)):460-470 doi:10.1053/j.ajkd.2019.12.008.
PMID: 32359821 - 4
Novel RRAGD Variants in Autosomal Dominant Kidney Hypomagnesemia and Therapeutic Perspectives.
Adella A, Jouret F, Madariaga L, et al.
Kidney international reports 2025; (10(10)):3640-3655 doi:10.1016/j.ekir.2025.07.035.
PMID: 41141537 - 5
[Bartter-Gitelman syndromes].
Blanchard A, Courand PY, Livrozet M, Vargas-Poussou R
Nephrologie & therapeutique 2020; (16(4)):233-243 doi:10.1016/j.nephro.2020.06.001.
PMID: 32622651 - 6
The Effect of Omeprazole on Urinary Magnesium Excretion in Children with Peptic Diseases.
Famouri F, Tavahen N, Gholami H, et al.
Journal of research in pharmacy practice 2024; (13(2)):53-57 doi:10.4103/jrpp.jrpp_35_24.
PMID: 39830949 - 7
Utility of fractional excretion of magnesium in diagnosing renal magnesium wasting in pediatric nephrology practice.
Awazu M, Matsumura K
Clinical biochemistry 2024; (131-132()):110807 doi:10.1016/j.clinbiochem.2024.110807.
PMID: 39059606 - 8
Thiazide but not loop diuretics is associated with hypomagnesaemia in the general population.
Kieboom BCT, Zietse R, Ikram MA, et al.
Pharmacoepidemiology and drug safety 2018; (27(11)):1166-1173 doi:10.1002/pds.4636.
PMID: 30095199 - 9
Long-term magnesium supplementation improves arterial stiffness in overweight and obese adults: results of a randomized, double-blind, placebo-controlled intervention trial.
Joris PJ, Plat J, Bakker SJ, Mensink RP
The American journal of clinical nutrition 2016; (103(5)):1260-6 doi:10.3945/ajcn.116.131466.
PMID: 27053384 - 10
Diverse Concepts in Definitions of Dilated Cardiomyopathy: Theory and Practice.
Myers MC, Breznen B, Zhong Y, et al.
Cardiology research 2024; (15(5)):319-329 doi:10.14740/cr1679.
PMID: 39420975 - 11
3-Tesla cardiac magnetic resonance imaging in primary dilated cardiomyopathy.
Kalekar T, Gupta A, Kumar M
African journal of thoracic and critical care medicine 2024; (30(1)):e844 doi:10.7196/AJTCCM.2024.v30i1.844.
PMID: 38756390 - 12
Utilities and Limitations of Cardiac Magnetic Resonance Imaging in Dilated Cardiomyopathy.
Cha MJ, Hong YJ, Park CH, et al.
Korean journal of radiology 2023; (24(12)):1200-1220 doi:10.3348/kjr.2023.0531.
PMID: 38016680 - 13
Utilization of Cardiac Magnetic Resonance Imaging for Assessing Myocardial Fibrosis in Prognosis Evaluation and Risk Stratification of Patients with Dilated Cardiomyopathy.
Feng XY, Zheng YC, Yang YX, et al.
Reviews in cardiovascular medicine 2025; (26(1)):25654 doi:10.31083/RCM25654.
PMID: 39867184 - 14
Association between late gadolinium enhancement and outcome in dilated cardiomyopathy: A meta-analysis.
Feng XY, He WF, Zhang TY, et al.
World journal of radiology 2023; (15(11)):324-337 doi:10.4329/wjr.v15.i11.324.
PMID: 38058605
This page explains tests used to evaluate kidney tubulopathy-dilated cardiomyopathy syndrome for informational purposes only and does not constitute medical advice. Your nephrologist, cardiologist, and genetics team should interpret your results in the context of your health.